Vaginal Dryness Clinical Trial
— PRV01Official title:
Evaluation Of Acceptability, Under Use in Real Conditions Of Two Vaginal Moistures ( 06260308 ) Indicated for Women With Vaginal Drying
Verified date | April 2020 |
Source | Libbs Farmacêutica LTDA |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The studies carried out to evaluate the safety and efficacy of products aimed at the intimate
area of women aim to confirm the absence of risk associated with its use, identify possible
feelings of discomfort and / or clinical signs resulting from the use of the product and
evaluate the benefits provided by the use of the product such as, gynecologically tested,
clinically tested, hydration for 72 hours, hydration, does not drip or drip little, feeling
of natural hydration, control of natural vaginal odor, preserves vaginal pH, does not promote
irritation, use vaginal topic, feeling of comfort, relief from dryness, easy use of the
applicator, the applicator does not cause discomfort during application, preferably use at
night, does not change the vaginal flora, reduces pain and discomfort during or shortly after
sexual intercourse, does not promote discomfort during or shortly after intercourse,
reduction of vaginal bleeding during or right after sexual intercourse, if there is a small
amount left in the applicator, the treatment is not compromised.
The research will be carried out with two new products for use in the internal intimate
region in up to 74 research participants (up to 37 participants per product - each group of
37 will use one of the products), which meet the required inclusion and exclusion criteria.
At the end of the treatment, the analysis must contain a minimum number of 30 participants
per product. Participants will use the test products for 22 (+ 2) days and will be evaluated
and monitored throughout the study by a gynecologist to verify the effectiveness of the
products and possible adverse events. In addition, a profile questionnaire will be applied at
the beginning of the study (T0 - day 1) and at the end of the study, the perceived efficacy
questionnaire (T22), to assess signs and symptoms of the efficacy and safety of the product
used.
Status | Completed |
Enrollment | 74 |
Est. completion date | April 6, 2020 |
Est. primary completion date | April 6, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Healthy research participants with an active sex life; - Skin and intact mucosa in the test region; - Agreement to adhere to the study's procedures and requirements and to attend the institute on the day (s) and time (s) determined for the assessments; - Ability to consent to their participation in the study; - Female research participants; - Menopausal participants of any age; - Participants who complain of vaginal dryness, classified at least as mild, and who present at least one of the following symptoms, in addition to vaginal dryness, also classified at least as mild (pain during or shortly after intercourse or discomfort during or soon after sexual intercourse). Exclusion Criteria: - Have used moisturizing creams and / or vaginal lubricants 05 days before the initial study visit; - Vaginal pathology in the product application area; - Have had sex less than 48 hours before the visit; - Have been diagnosed with urogenital or vaginal infection in the last 30 days; - Have used topical or systemic antibiotics, antifungals, hormone-based creams or treatment for vaginal atrophy in the last six weeks; - Immune failure; - Current use of the following medications for topical or systemic use: corticosteroids, immunosuppressants and antihistamines and in the last 7 days; - History of reaction to the category of the product tested; - Present vaginal bleeding on the day of visits; - Other diseases or medications that may directly interfere with the study result or endanger the health of the research participant, at the discretion of the investigator. |
Country | Name | City | State |
---|---|---|---|
Brazil | Augusto Theodoro de Figueiredo | São Paulo |
Lead Sponsor | Collaborator |
---|---|
Libbs Farmacêutica LTDA |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intensity of clinical signs (Visual gynecological examination) | Visual examination of the vulva, vagina and cervix using a speculum. Objective vaginal signs will be described, such as: inflammation, edema, presence of abrasions and presence of deepithelialization of the vaginal mucosa in the initial (T0 - Day 1).Each clinical sign will be classified using a scale from 0 to 3 from the best to the worst scenario (0 - Absent, 1 - Mild, 2 - Moderate or 3 - Intense). | day 1 | |
Primary | Intensity of clinical signs (Visual gynecological examination) | Visual examination of the vulva, vagina and cervix using a speculum. Objective vaginal signs will be described, such as: inflammation, edema, presence of abrasions and presence of deepithelialization of the vaginal mucosa in the final (T22- Day 22).Each clinical sign will be classified using a scale from 0 to 3 from the best to the worst scenario (0 - Absent, 1 - Mild, 2 - Moderate or 3 - Intense). | day 22 | |
Primary | Vaginal pH measurements | Before using the product (T0 - day 1), the vaginal pH will be evaluated, with the aid of a speculum, using colorimetric pH measuring tapes, with a gradual scale of 2 to 9. The tapes will be applied in contact with the right lateral vaginal wall, without touching the cervix or cervical mucus, due to the pH difference. The cervix, as well as the cervical mucus, have a pH more alkaline than the vagina, and may interfere with the result that will be evaluated by colorimetric approximation using the standard template |
day 1 | |
Primary | Vaginal pH measurements | Before using the product after 22 + 2 days (T22), the vaginal pH will be evaluated, with the aid of a speculum, using colorimetric pH measuring tapes, with a gradual scale of 2 to 9. The tapes will be applied in contact with the right lateral vaginal wall, without touching the cervix or cervical mucus, due to the pH difference. The cervix, as well as the cervical mucus, have a pH more alkaline than the vagina, and may interfere with the result that will be evaluated by colorimetric approximation using the standard template |
day 22 | |
Primary | Bacterioscopic collection | Before using the product (T0 - day 1) and after 22 + 2 days (T22), the bacterioscopic collection of vaginal secretion will be performed to quantify the microorganisms present in it in order to assess the non-interference of the use of the product in the flora vaginal. The collection of vaginal material from the participants will be performed by a gynecologist with the insertion of a speculum in the vagina. The excess cervical mucus will be removed with the aid of MOD_PRO_CEP Rev. 03 All-SE-UG-EP-pH-FL-062603-07 / 08-04-18-PRV01 cotton swab. Then, the swabs indicated for collection will be inserted and rotated for a few seconds on the bottom of the vaginal sac.The swabs containing the samples will be immediately placed in sterile test tubes and sent to the laboratory for microbiological analysis. |
days 1 and 22 | |
Primary | Visual assessment of product accumulation in the mucosa | Visual assessment of accumulation of product adhered to the mucosa will be performed after 72 hours or more, considering the study window (+2 days), without using the product (T22): 0: Absent Little buildup Moderate accumulation Intense accumulation |
after 72 hours | |
Primary | Vaginal Health Index | Classification by the gynecologist of the parameters present in the vaginal health score (Vaginal Health Index) before and after using the product (T0 - day 1 and T22 + 2 days), as shown below. During the specular examination, a vaginal health index will be evaluated by the gynecologist, with scores from 1 to 5. A lower score corresponds to greater urogenital atrophy (worse outcome) |
after 72 hours | |
Primary | Teste de Contato (patch test) | If, during the research, any participant has an adverse reaction such as contact dermatitis, they will be subjected to epicutaneous tests. The evaluation scale to be used will be the scale recommended by the International Contact Dermatitis Investigator Group - ICDRG - | up to 22 day | |
Secondary | Evaluation of Effectiveness Perceived by Research Participants | Before using the product (T0 - day 1) of use, the research participants will be instructed to self-assess themselves through of questionnaires.A point scale will be used, using a numerical scale (0 to 4) to assess this perception (0 - worse outcome to 4-better outcome) | day 1 | |
Secondary | Evaluation of Effectiveness Perceived by Research Participants | Before using the product after 22 + 2 days (T22) of use, or only after using the product (T22), the research participants will be instructed to self-assess themselves through of questionnaires.A point scale will be used, using a numerical scale (0 to 4) to assess this perception (0 - worse outcome to 4-better outcome) | day 22 | |
Secondary | Rate of Gynecological Adverse Reactions | All reactions will be classified according to their intensity, according to the classification below (From best -mild to worst scenario -intense): Mild: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not interfering with the participant's usual functions or normal daily activities. Moderate: enough discomfort present to cause interference with a part of the participant's usual functions or normal daily activities. Intense: Extreme difficulty, causing significant damage to functioning or disability; significantly interferes with the participant's usual functions; prevents normal daily activities. |
up to 22 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT01170195 -
Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03666819 -
Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy
|
Phase 2 | |
Completed |
NCT02937805 -
Effects of a Moisturizing Cream on Vaginal and Vulvar Mucous Membranes
|
N/A | |
Completed |
NCT02994342 -
Efficacy and Tolerability Study of ZP-025 Vaginal Gel for the Treatment of Vaginal Dryness
|
N/A | |
Recruiting |
NCT05913479 -
Evaluation of the Efficacy and Safety of Mucogye® Gel as a Moisturizer
|
N/A | |
Completed |
NCT03307044 -
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
|
N/A | |
Recruiting |
NCT03714581 -
Laser Therapy Following Radiotherapy for Gynecological Cancer
|
N/A | |
Completed |
NCT01948583 -
Humectant Activity of a New Formulation of Gynomunal® Vaginalgel
|
Phase 4 | |
Completed |
NCT03178825 -
Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause
|
N/A | |
Completed |
NCT03372720 -
Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors
|
N/A | |
Not yet recruiting |
NCT06282614 -
Performance and Safety of MUCOGYNE® Ovule as a Moisturizer
|
N/A | |
Completed |
NCT02176083 -
Reproductive Health Survivorship Care Plan Pilot
|
N/A | |
Completed |
NCT04908124 -
A Clinical Investigation Into the Effectiveness and Safety of Five Water Based Personal Lubricants.
|
Phase 3 | |
Not yet recruiting |
NCT05156502 -
To Assess Signs and Symptoms in Women Affected by GSM After One Cycle of Pixel CO2-Alma Fractionated Laser
|
N/A | |
Completed |
NCT02638337 -
Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause
|
Phase 3 | |
Not yet recruiting |
NCT02987647 -
Perception of Efficacy, Safety and Tolerability of Three Non-hormonal Intravaginal Gels and Hormone Cream
|
Phase 4 | |
Not yet recruiting |
NCT03782961 -
Evaluation of Viscosity of a Vaginal Moisturizer
|
Phase 4 | |
Withdrawn |
NCT01724242 -
Vaginal DHEA for Women After Breast Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT01697345 -
Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy
|
Phase 0 | |
Completed |
NCT02269826 -
Efficacy and Safety of Non-hormonal Vaginal Preparations in Treating Vaginal Dryness
|
N/A |